Combinations ;
1. Saxagliptin/Metformin
- see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Onglyza | Astra zeneca | 2.5mg | 30 | Tablet | per tablet | KES 4,357.00 | |
| Saxagliptin More info | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mode Of Action | Stimulate insulin release and suppress glucagon release. | ||||||||||||||||||||||||
| Drug Indication | Treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise as monotherapy or in combination therapy with other antidiabetic agents to improve glycemic control | ||||||||||||||||||||||||
| Precautions | Disease-related concerns:
• Renal impairment: Use with caution in patients with moderate-to-severe renal dysfunction and end-stage renal disease (ESRD) requiring hemodialysis; dosing adjustment required. Concurrent drug therapy issues: • High potential for interactions: Use with caution in patients taking strong CYP3A4/5 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin; also see Drug Interactions); dosage adjustment of saxagliptin is required. • Insulin secretagogues: Use caution when used in conjunction with insulin secretagogues (eg, sulfonylureas); risk of hypoglycemia is increased. Monitor blood glucose closely; dosage adjustments of the insulin secretagogue may be necessary |
||||||||||||||||||||||||
| Contra-Indications | There are no contraindications listed within the manufacturer’s labeling | ||||||||||||||||||||||||
| Side Effects | Note: Frequencies and adverse reactions reported with
monotherapy unless otherwise noted.
1% to 10%: Cardiovascular: Peripheral edema (≤4%; incidence increased in conjunction with thiazolidinediones: ≤8%) Central nervous system: Headache (7%) Endocrine & metabolic: Hypoglycemia (≤6%; incidence increased in conjunction with insulin secretagogues: ≤15%) Gastrointestinal: Abdominal pain (2%), gastroenteritis (2%), vomiting (2%) Genitourinary: Urinary tract infection (7%) Hematologic: Lymphopenia (≤2%; dose related) Respiratory: Sinusitis (3%) Miscellaneous: Hypersensitivity reactions (2%; including urticaria and facial edema) <1% (Limited to important or life-threatening): Creatinine increased, creatine phosphokinase increased, idiopathic thrombocytopenic purpura, rash |
||||||||||||||||||||||||
| Dosage | Dosing: Adult
Type 2 diabetes: Oral: 2.5-5 mg once daily Concomitant use with strong CYP3A4/5 inhibitors: 2.5 mg once daily Concomitant use with insulin secretagogues: Reduced dose of the insulin secretagogue (eg, sulfonylurea) may be needed Dosing: Geriatric Refer to adult dosing |
||||||||||||||||||||||||
| Special Information | Do not break the tablet. | ||||||||||||||||||||||||
| Pregnancy Category | B | ||||||||||||||||||||||||
| Pregnancy Category Description | |||||||||||||||||||||||||
| Drug Category | Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor | ||||||||||||||||||||||||
| Drug Sub-Category |
Combinations ; 1. Saxagliptin/Metformin XR
|
||||||||||||||||||||||||